摘要
目的 :观察153 Sm -EDTMP对骨转移癌患者血浆TXB2 、6 -K -PGF1α水平的影响。方法 :5 5例骨转移癌患者 ,肘静脉注射153 Sm -EDTMP ,剂量按 (18 5～ 37)MBq/kg ,放射免疫分析治疗前后不同时间血浆TXB2 、6 -K -PGF1α的浓度。结果 :血浆TXB2 治疗前、治疗 (1～ 2 )月与治疗 3月后无显著差异 ;6 -K -PGF1α治疗后 (1～ 2 )月较治疗前明显降低 ,3月后升高 ,骨痛缓解率高。结论 :153 Sm -EDTMP可调节 6 -K -PGF1α水平 ,这可能与其治疗骨转移癌骨痛的作用有关。
Objective To observe the effects of 153Sm-EDTMP treatment on plasma levels of TXB 2 and 6-K-PGF 1α in patients with bone metastases. Methods Fifty-five patients were treated with intravenous 153Sm-EDTMP at the dose of 18.5～37MBq/kg. The plasma TXB 2 and 6-K-PGF 1α levels were repeatedly determined by RIA before treatment, 1～2 months and 3 months after treatment. Results Plasma TXB 2 levels didn’t significantly change at these three determinations P>0.05; 6-K-PGF 1α levels decreased significantly by 1～2 months but increased again at 3 month (P<0.01) after treatment with marked amelioration of the bone pain. Conclusion 153Sm-EDTMP could regulate the levels of 6-K-PGF 1α which might be releveant to the treatment effects in patients with bone metastases.
出处
《放射免疫学杂志》
CAS
2004年第3期183-184,共2页
Journal of Radioimmanology
